CHRONIC SPONTANEOUS URTICARIA TREATED WITH OMALIZUMAB: WHAT DIFFERENTIATES EARLY FROM LATE RESPONDERS?

Riccardo Asero, MD
Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano (MI), Italy

KEY WORDS: Chronic Urticaria, Omalizumab, Biomarkers, IgE, D-dimer

Conflict of Interest: None
Funding: None

Address:
Dr Riccardo Asero,
Ambulatorio di Allergologia, Clinica San Carlo,
20037 Paderno Dugnano (MI), Italia
r.asero@libero.it
To the Editor

Omalizumab is the first choice treatment for severe chronic spontaneous urticaria (CSU) patients who are unresponsive to second-generation antihistamines even at higher than licensed dose (1). The drug is effective in about 85% of patients, inducing a dramatic drop in UAS7 levels. The clinical effect can be very rapid (in about 70% of patients, the so-called early or fast responders, the effect may appear as early as 3-5 days after the first administration), or slow (in about 15% of patients, the so-called late or slow responders, 3-4 months of treatment are needed to see a benefit). The drug is ineffective in the remaining 15% (2).

Several recent studies have shown the association between elevated baseline total IgE levels and a positive response to omalizumab, with non-responders showing significantly lower IgE (3-5). A possible “autoallergic” pathogenesis mediated by IgE specific for self-proteins may reasonably explain a rapid response to omalizumab in some patients with CSU (6,7). In contrast, the reasons why a proportion of patients take months to respond to the drug are less clear. This subpopulation might coincide with patients showing an IgG-mediated autoimmune process able to activate mast cells and basophils via the high affinity IgE receptor, either directly (by IgG-anti-FcεRI) or indirectly (by IgG directed against receptor-bound IgE) (8,9).

In this case, the effect of omalizumab would rely on the down-regulation of IgE receptors, a process that would take some months (10). From the clinical point of view, patients showing a rapid or slow response to omalizumab have not been compared so far. The present study investigated the clinical and serological features in these two subsets of CSU patients.

One hundred and thirty patients (M/F 53/77; mean age 50.6 years (range 13-89 years) with severe CSU (UAS-7 > 30) unresponsive to second generation antihistamines at any dosage and successfully submitted to treatment with Omalizumab 300 mg/month for at least 3 months were studied. Based on their response to Omalizumab, patients were classified as early responders (drop of at least 50% of UAS-7 from baseline level already 1 month after the first administration; n=108) and late responders (no appreciable clinical effect one month after the first administration, but drop of at least 50% of baseline UAS-7 after 3 months of treatment; n=22). Age, sex, disease duration, and several baseline clinical parameters including ESR, CRP, thyroid autoimmunity, total IgE, D-dimer, and atopic status (as assessed by SPT with a large panel of
commercial extracts of both seasonal and perennial respiratory allergens) were compared between the two subsets. The chi-square test with Yates’ correction, the two-tailed Student’s t-test, or the Mann-Whitney non-parametric test were used where appropriate. Probability values less than 5% were regarded as statistically significant. The internal review board approved the study, and all the patients signed an informed consent to use their clinical data in an anonymous form.

The study subpopulations are compared in table 1. The two groups did not differ in gender, mean age, disease duration, atopic status, inflammation markers, and thyroid autoimmunity. In contrast, early responders showed a significantly higher proportion of patients showing elevated (> 100 UI/ml) baseline total IgE (67% vs 33%, respectively; p < 0.05). Of those showing elevated total IgE at baseline, only 16/41 (39%) and 2/5 (40%) were atopic among early and late responders, respectively. Although median total IgE levels were much higher among early responders (181 UI/ml vs 42 IU/ml for early and late responders, respectively), probably due to the small number of late responders the difference between the two subgroups did not reach the statistical significance.

To the best of our knowledge, this is the first study comparing the clinical features of the two specific subsets of CSU patients responding to anti-IgE therapy, namely the early and late responders. The two subsets of omalizumab responders were virtually identical with the only difference of a much larger proportion of patients showing elevated IgE levels in the early responders group. This observation is in keeping with previous studies showing the direct relationship between elevated IgE levels and the response to anti-IgE treatment in the general CSU population (3-5). It is conceivable that in these patients elevated total IgE may mirror the predisposition to synthesize autoreactive IgE antibodies that the anti-IgE mAb rapidly binds and eliminates from the circulation. It has also been shown that omalizumab is able to bind IgE fixed to the high affinity receptor and to detach them (11), which leads (in a long term) to a downregulation of the receptor. In patients showing a slow response to the omalizumab it is possible that this latter mechanism of action is the most important. In effect, a very recent study seems to suggest that the contemporary presence of IgE and IgG-mediated autoimmunity (particularly against the high affinity IgE receptor) may slow down the clinical response to the drug (12).
REFERENCES


Table 1: Clinical and serological characteristics of patients showing a prompt or late response to Omalizumab

<table>
<thead>
<tr>
<th></th>
<th>Early responders (n=108)</th>
<th>Late responders (n= 22)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>M/F</td>
<td>44/64</td>
<td>9/13</td>
<td>NS</td>
</tr>
<tr>
<td>Mean age (years)</td>
<td>49.7</td>
<td>54.8</td>
<td>NS</td>
</tr>
<tr>
<td>Median disease duration in months (range)</td>
<td>12 (2-600)</td>
<td>10.5 (2-300)</td>
<td>NS</td>
</tr>
<tr>
<td>Atopic status (%)</td>
<td>30 (27%)</td>
<td>9/22 (41%)</td>
<td>NS</td>
</tr>
<tr>
<td>Thyroid autoimmunity (%)</td>
<td>20/98 (20%)</td>
<td>3/7 (14%)</td>
<td>NS</td>
</tr>
<tr>
<td>D-dimer &gt; 500 ng/ml</td>
<td>42 (39%)</td>
<td>9/11 (43%)</td>
<td>NS</td>
</tr>
<tr>
<td>Total IgE &gt; 100 IU/ml</td>
<td>41/61 (67%)</td>
<td>2/15 (33%)</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>Median IgE level</td>
<td>181 (9-1139)</td>
<td>5 (5-1000)</td>
<td>NS</td>
</tr>
<tr>
<td>Elevated CRP or ESR</td>
<td>24 (22%)</td>
<td>3 (18%)</td>
<td>NS</td>
</tr>
</tbody>
</table>